IDIOPATHIC PULMONARY FIBROSIS DRUG MARKET TO GROW TO $4.6 BILLION IN 2020

New Idiopathic Pulmonary Fibrosis Report Now Available from Decision Resources

November 10, 2011—Burlington, Mass.—Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the idiopathic pulmonary fibrosis (IPF) drug market is forecasted to grow to $4.6 billion in 2020 in the United States and Europe. Increasing diagnosed and drug-treated populations and the launch of five drugs with novel mechanisms of action are key drivers of this growth. Idiopathic pulmonary fibrosis is one of the most common interstitial lung diseases, and it is the most prevalent pulmonary fibrotic disease.

Until the launch of InterMune’s Esbriet in Germany earlier this year, no drugs were licensed for IPF in either the United States or Europe. IPF has traditionally been treated with antioxidants and immunosuppressants, but these agents’ lack of efficacy accounts for their limited use and low overall rates of drug treatment for IPF. Novel agents such as Esbriet along with Boehringer Ingelheim’s Vargatef, Janssen Biotech’s carlumab, FibroGen’s FG-3019 and Novartis’s QAX-576, which are expected to launch in the United States and Europe within the next ten years, will expand the drug-treated population because they will offer disease modification.

“There is significant commercial opportunity in the IPF drug market. While pulmonologists we surveyed are excited by the level of research and drug development for IPF, they also point out that IPF pathogenesis is a multistep process involving many signaling pathways. They believe that polypharmacy will prove more effective than monotherapy, but would like to see clinical investigations in this area,” said Analyst Mary Argent-Katwala, Ph.D. “Data to support the use of polypharmacy in IPF treatment will be important moving forward.”

These findings are from Decision Resources new Idiopathic Pulmonary Fibrosis report, which assesses commercial opportunity of the IPF market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes a market forecast and primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

###

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com
 


Search Reports

Decision Resources Group brands include: